4565 Nxera Pharma
- 1119
- -21-1.84%
Nxera Pharma News
Open H, Ship HD, etc. (additional) Rating
Upgrade - Bullish code stock name securities company previously changed afterwards --------------------------------------------- <2413> M3 City "2" "1" <4565> Nexera Pharma City "2" "1" <7269> Suzuki JPM "Neutral" "Overweight" Downgrade - Bearish code stock name securities company previously changed afterwards --------------------------
Rating [security companies rating]
Upgraded - Bullish Code Stock Name Securities Company Previous After Change -------------------------------------------------- <3110> Nittohobo Tokai Tokyo "Neutral" "Out P" <9005> Tokyu SBI "Hold" "Buy" <7269> Suzuki JP Morgan "Neutral" "Over W" <2413> Emisuri City "Hold" "Buy" <4565> Nexus Era P City "Hold"
Nxera Pharma Gains Milestone Payment in Sleep Disorder Collaboration
Stocks that moved the previous day part2 include Nippon Ham, Taiyo Koki, Fuji Kogyo E&C, etc.
Stock name <Code> 5-day closing price⇒Day-over-day change BIPROGY <8056> 4420 -3187-Forecasted decrease in ordinary income for the September period. Nippon Ham <2282> 4754 -516Negative views such as sluggish improvement in revenue of processed business. Tokyo Electron Devices <2760> 3065 -265Negative sentiment towards double-digit operating profit decline in the first half results. Rigaku <268A> 1200 -50Majority favors selling due to awareness of overhead resistance. Nexela Pharma <4565> 1174 -397-9
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
Sumitomo Electric, Mabuchi, etc. (Additional) Rating
Upgrade - Bullish Code Stock Name Securities Company Previous After Change ---------------------------------- <6080> M&A Capcom Maclory "Under P" "Out P" <6752> Panasonic HD Maclory "Neutral" "Out P" Target Stock Price Change Code Stock Name Securities Company Previous After Change ----------------------------------
November 5th [Today's Investment Strategy]
Specializing in clutches for motorcycles and autos.
Focus on FCC and Organo, are DMG Mori Seiki and Yamaha weak?
In the US stock market on the 4th, the dow jones industrial average closed down 257.59 points at 41,794.60, the nasdaq composite index fell 59.93 points to 18,179.98, and the chicago nikkei 225 futures were 255 yen higher at 38,375 yen than osaka midday trading. The exchange rate is 1 dollar = 152.10-20 yen. In today's Tokyo market, FCC <7296> announced a 55.3% increase in operating profit for the first half, implemented commemorative dividends, and also announced a share buyback with a limit of 2.5% of the issued shares, with a 2.3% increase in operating profit for the first half and an increase in issued shares of 1.
KDDI announces a 2.3% increase in operating profit in the second quarter to 573 billion yen, along with a share buyback and split.
KDDI<9433> announced its financial results for the second quarter of the fiscal year ending March 2025, with revenue increasing by 2.8% year-on-year to 2 trillion 855.7 billion 13 million yen, and operating profit increasing by 2.3% to 573 billion 86 million yen. The non-communications sectors such as enterprise digital transformation (DX) support services and finance performed well. The financial estimates for the fiscal year ending in March 2025 remain unchanged. Additionally, up to 100 billion yen, equivalent to 1.39% of the total number of issued shares (excluding treasury stock), is 2800.
Nxera Pharma: Business highlights and consolidated financial results for the 3rd quarter (January-September) of the fiscal year ending 2024/12
Nxera Pharma: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [IFRS] (consolidated)
Asahi Kasei, TDK, Mitsui Chemicals, kddi corporation (1st day)
※Please note that the above calendar is subject to change depending on the company's circumstances.---------------------------------------November 1st (Friday)＜2229＞Calbee ＜2282＞Nippon Ham＜2296＞Itoham Yonekyu Holdings ＜2349＞NIID ＜2440＞Gurunavi ＜2480＞Sysmex＜2551＞MarsaInc ＜2730＞Edion＜27
Cosmos Pharmaceuticals, Money Forward, etc. (additional) Rating
Upgrade - Bullish Code Stock Name Securities Company Original After Change -------------------------------------------------- <4902> Konica Minolta McCaulley "Neutral" "Outperform" Target Stock Price Change Code Stock Name Securities Company Original After Change -------------------------------------------------- <319
Nxera Pharma Wins Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024
Stocks that moved the previous day part1: Ryomo Systems, Sansan, Disco, etc.
Obtained a domestic patent related to the method for predicting the efficacy of rheumatoid arthritis treatment drugs and evaluating the activity of rheumatoid arthritis.
Nxera Pharma to Host R&D Day 2024
CellSys hits new high [stocks hitting new highs and lows]
Top gainers on the TSE Prime are Wright Industries <1926> and Sumitomo Densetsu <1949> with a total of 39 stocks. Top losers on the TSE Prime are Nextage <3186> and Nexella Pharma <4565> with 5 stocks. "TSE Prime" "TSE Standard" "TSE Growth" new highs new lows new highs new lows new highs new lows 10/08 39 5 12 10 5 7 10/07 80 0
October 1st [Today's investment strategy]
[Fisco Selected Stocks] [Material Stocks] Nexera Pharma <4565> 1226 yen (10/1) Drug discovery venture. Former Sosei Group. Its subsidiary Nexera Pharma Japan has announced the signing of a partnership agreement with Shionogi <4507> regarding the distribution and sales of the insomnia treatment drug "Cubick Tablets" in Japan, and resolved its sales efforts with Mochida Pharmaceutical <4534>. Shionogi will independently conduct distribution and sales activities in Japan. [Emerging Markets]
Pay attention to Zojirushi Mahobin and IBJ, Dai Seki, etc. are soft.
In the U.S. stock market on the 1st, the NY Dow Jones Industrial Average closed at 42,156.97, down 173.18 points, the Nasdaq Composite Index closed at 17,910.36, down 278.81 points, and the Chicago Nikkei 225 Futures closed at 38,030 yen, down 740 yen from the Osaka day session. The exchange rate was 1 dollar = 143.50-60 yen. In today's Tokyo market, Zojirushi Mahobin <7965> turned to profit by increasing operating profit for the third cumulative quarter by 6.5% from a 2.4% decrease in the previous period, and announced a share buyback of up to 1.59% of the issued shares.
Nxera Pharma Partners With Shionogi on Insomnia Drug
Analysis
Price Target
No Data
No Data